We are extremely proud to announce that recently, our Chief Science Officer Dr. Ravi Birla jointly published a paper in the prestigious scholarly journal, APL Bioengineering with Stuart K. Williams, a renowned expert within cardiovascular research and biomedical engineering.
From the entire BIOLIFE4D team, we would like to congratulate Dr. Birla on this remarkable accomplishment. It’s an honor to be published in APL Bioengineering, a journal dedicated to research and scientific advancements relating to engineering of biological systems. This paper, “3D bioprinting and its potential impact on cardiac failure treatment: An industry perspective” depicts how 3D printing technologies are emerging as an innovative solution for the treatment of cardiac failure. Overall, it provides an overview on the various strategies that have been used to bioengineer bioartificial hearts and outlines how the advances in stem cell engineering, bioreactor development, and 3D bioprinting technology have impacted the field of whole heart bioengineering. We encourage you and your network to read this paper and engage in discussion about 3D bioprinting’s potential impact on treatment of cardiac failure.
Successfully publishing peer-reviewed research in a scholarly journal is an incredible validation of our scientific progress towards our ultimate goal of 3D bioprinting human hearts viable for transplant. And with your continued support we are closing in on our goal of bringing this life-saving technology to the market.
To all of our investors and supporters, we thank you so much for your help and encourage you to share our journey with your network. If you haven’t already, be sure to connect with us on Facebook, Twitter, and LinkedIn to follow our journey as we strive to find a solution and forever innovate heart disease treatment.